Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 321-325

  Minor, David R ^a   Chin, Kevin ^b   Kashani Sabet, Mohammed ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti CTLA4; Colitis; Immune related; Infliximab; Ipilimumab; Melanoma

Indexed keywords

BUDESONIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; ENEMA; HYDROCORTISONE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; MESALAZINE; NARCOTIC AGENT; STEROID;

ADD ON THERAPY; ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLITIS; CONJUNCTIVITIS; DIARRHEA; DRUG ERUPTION; EVENING DOSAGE; HOSPITALIZATION; HUMAN; IMMUNOPATHOLOGY; MALE; MELANOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; VITILIGO;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CLINICAL TRIALS AS TOPIC; COLITIS; DIARRHEA; HUMANS; HYDROCORTISONE; MALE; MELANOMA; MESALAMINE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 67650848410     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0607     Document Type: Article

References (20)

1. Weber J. Review of anti-CTLA antibody ipilimumab: Case studies of clinical response and immune-related toxicities. Oncologist 2007;12:864.
2. Kirkwood JM, Tarhini AA, Paneli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445.
3. Urba WJ, Weber JS, O'Day DJ, et al. Long-term survival of patients with advanced melanoma who received ipilimu-mab administered at 10mg/kg every 3 weeks for 4 doses (induction dosing). J Clin Oncol 2008;26(Suppl):7s.
4. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283.
5. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825.
6. Weber JS, Berman D, Siegel J, et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naïve and previously treated patients with advanced melanoma. J Clin Oncol 2008;26(Suppl):7s.
7. Smith FO, Goff, SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother 2007;30:130.
8. Lin R, Yellin MJ, Lowy I, et al. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of intestinal perforation and/or colectomy. J Clin Oncol 2008;26(Suppl)7s.
9. Beer TM, Slovin SF, Higano CS, et al. Phase 1 trial of ipili-mumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008;26(Suppl):7s.
10. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244.
11. Fries W, Muja C, Crisafulli C, et al. Dynamics of enterocyte tight junctions: Effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol 2008;294:G938.
12. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb associated panenteritis: A histologic and immunohistochemical analysis. Am J Surg Path 2008;32:1130.
13. Berman D, Parker SM, Chasalow SD, et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. J Clin Oncol 2008; 26(Suppl):7s.
14. Lichenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621.
15. Lin J, Ziring D, Desai S, et al. TNFa blockade in human diseases: An overview of efficacy and safety. Clin Immunol 2008;126:3.
16. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open, randomized trial. Lancet 2008;371:660.
17. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007;13:5238.
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM 2005;353:2462.
19. Poggioli G, Laurenti S, Campieri M, et al. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301.
20. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor-alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542.